MedWatch

ALK's Q1 better than predicted on top and bottom line

Allergy firm ALK upgrades its financial outlook for the rest of the year following a first quarter that exceeded expectations.

Photo: ALK / PR

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Ambu fails to live up to revenue forecasts

The number of endoscopes sold is significantly higher than what the market had predicted in Ambu's second quarter. However, this has not brought about the kind of revenue that analysts had expected. The full-year outlook is maintained.

Tough competition forces innovation at Ambu

Ambu is intensifying its efforts to create the next generation of its duodenoscopes. A number of competitors are circling, and an upcoming tender is a good opportunity for income. CEO Juan Jose Gonzalez calls the new duodenoscope the biggest earner of the future.

Analyst on new Bose hearing aid: "Won't disrupt Danish manufacturers"

US electronics company Bose's announced launch of a new, cheap self-tuning hearing aid won't cause sales to plummet for established hearing aid manufacturers, analysts believe. Demant welcomes the competition and WSA plans to test Bose's new solution to understanding its technology.

Further reading

Related articles

Latest news

See all jobs